Back

Incident cardiac abnormalities after CAR-T cell therapy in children: a single center experience.

21 June 2025 (13:00 - 14:00)
Organised by: Logo
Congress Presentation Part of: Navigating cardiovascular challenges in immune checkpoint inhibitor and CAR-T therapy Cardio-Oncology CCO Premium Access ESC Cardio-Oncology 2025 Council of Cardio-Oncology

About the speaker

Photo
Doctor Rossana Palumbo

Bambino Gesu Pediatric Hospital, Rome (Italy)

8 More presentations in this session

Presentation thumbnail
Right ventricular dysfunction in hematologic patients exposed to Chimeric Antigen Receptor (CAR)-T cells therapy: results from the prospective CARdio-TOX study.
Doctor L. Amore (Rome, IT)
Abstract Slides
Presentation thumbnail
Abatacept vs. conventional therapy in immune checkpoint inhibitor-associated myocarditis
Doctor T. Imaoka (Kashiwa, JP)
Abstract Slides
Presentation thumbnail
Cardiac dysfunction in patients with kidney cancer receiving immunotherapy
Doctor M. Spisarova (Olomouc, CZ)
Abstract Slides
Presentation thumbnail
High incidence of immune checkpoint inhibitor therapy related subclinical cardiac dysfunction in patients with extracardiac immune related adverse events
Associate Professor R. Mincu (Essen, DE)
Abstract Slides
Presentation thumbnail
Mycophenolate mofetil as second-line therapy for steroid-refractory ICI-induced myocarditis
Doctor S. Jimenez-Marrero (Barcelona, ES)
Abstract Slides

Access the full session

Session thumbnail
Navigating cardiovascular challenges in immune checkpoint inhibitor and CAR-T therapy

The Event

Event poster

ESC Cardio-Oncology 2025

21 June 2025 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Right ventricular dysfunction in hematologic patients exposed to Chimeric Antigen Receptor (CAR)-T cells therapy: results from the prospective CARdio-TOX study.
thumbnail
Congress Presentation
Cardiovascular complications of chimeric antigen receptor (CAR)-t cell therapy: insights from a regional cardio-oncology program
thumbnail
Congress Presentation
Cardiovascular adverse events after CAR-T, BiTEs and TILs therapies: a systematic review and meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources